ABIVAX Société Anonyme · NASDAQ (us_market)
Healthcare · Biotechnology · France
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-24$145.31 RISE2026-04-29$106.24 PEAK2026-05-29$132.63 156d | -26.9% 126d | Missed | Missed | — | — | +24.8% 30d | Missed |
DROP2025-12-24$145.31 RISE2026-03-30$101.50 PEAK2026-05-29$132.63 156d | -30.1% 96d | Missed | Missed | — | — | +30.7% 60d | Missed |
DROP2025-03-06$8.29 RISE2025-05-23$5.67 PEAK2025-08-04$72.07 151d | -31.6% 78d | Missed | Missed | — | — | +1171.1% 73d | Missed |
DROP2024-12-04$8.89 RISE2025-04-08$5.17 PEAK2025-06-06$8.19 184d | -41.8% 125d | Missed | Missed | — | — | +58.4% 59d | Missed |
DROP2024-09-27$11.60 RISE2025-02-05$5.85 PEAK2025-03-06$8.29 160d | -49.6% 131d | Missed | Missed | — | — | +41.7% 29d | Missed |
DROP2024-06-12$14.43 RISE2024-10-10$8.97 PEAK2024-10-28$10.69 138d | -37.8% 120d | Missed | Missed | — | — | +19.2% 18d | Missed |
DROP2024-04-24$15.89 RISE2024-08-16$10.85 PEAK2024-08-30$12.71 128d | -31.7% 114d | Missed | Missed | — | — | +17.1% 14d | Missed |
No scored news yet for a sentiment trend.
Does Abivax SA Sponsored ADR (ABVX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Citizens analyst Jason N. Butler reiterates Abivax (NASDAQ:ABVX) with a Market Outperform and maintains $131 price target.
Abivax has reported first-quarter 2026 results, with revenue of €1.34 million and a net loss of €48.47 million, alongside updated loss-per-share metrics. The company also released three-year interim data from its long-term obefazimod ulcerative colitis trial, showing durable clinical remission and no new safety signals over up to seven years of treatment. Next, we’ll examine how the long-term obefazimod data and upcoming Phase 3 and regulatory milestones shape Abivax’s investment...
Interim intent to treat ("ITT") analysis from Study 108 supports strong durable clinical remission in moderately to severely active ulcerative colitis ("UC") patients treated with obefazimod Following two to four
Long-time shareholders are already pretty satisfied with these companies, but there might be even more upside ahead.
This clinical-stage biotech develops therapies for rare muscle diseases, leveraging its FORCE platform to target significant unmet needs.
Ocular Therapeutix delivers ophthalmic therapies with hydrogel technology and a pipeline targeting retinal and glaucoma conditions.
This biotech develops therapies for neurodegenerative diseases, advancing a broad pipeline through strategic pharmaceutical partnerships.
Beam Therapeutics develops precision genetic medicines using base editing technology to target serious inherited diseases.
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases.
Xenon Pharmaceuticals develops therapies for neurological disorders, with a pipeline targeting epilepsy and related conditions.
Specializing in monoclonal antibody therapies, this clinical-stage biotech targets severe autoimmune and inflammatory diseases.
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary SharesCash runway remains into Q4 2027, supporting continued funding of clinical programs and
Abivax is a buy, with Obefezimod showing best-in-class efficacy and safety in ulcerative colitis and potential in Crohnâs disease. Click for more on ABVX stock.
Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B. CNTA stock surges 45% as Lilly expands its neuroscience and sleep medicine pipeline.
They could make important breakthroughs in their target markets.
Abivax is advancing obefazimod, a first-in-class oral therapy for UC and CD, with major upcoming data catalysts. Click here to find out why ABVX is a Hold.
Abivax plans fundraising after June trial data as CEO signals no urgency to sell amid takeover speculation and strong stock momentum.
Barclays analyst Etzer Darout maintains Abivax (NASDAQ:ABVX) with a Overweight and raises the price target from $142 to $148.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ABVX | +12.77% | +17.26% | -1.65% | +2103.16% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +9.80% | +22.97% | +1.79% | +2090.47% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 1.29M | $143.24M | 0.01% | Trimmed-5.8% | 2026-03-31 |
| Citadel | multi-strat | 637.7K | $71.01M | 0.09% | Trimmed-73.5% | 2026-03-31 |
| DEShaw | quant | 50.5K | $5.63M | 0.00% | Added+187.2% | 2026-03-31 |
| StateStreet | passive | 5.0K | $557.53K | 0.00% | Added+15.8% | 2026-03-31 |
| TRowePrice | fundamental | 691.7K | $77.02K | 0.01% | Added+6.1% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-09-14upcoming | — | — | — |
| 2026-05-22 | -0.81 | -0.71 | +12.81% |
| 2026-03-23 | -1.04 | -1.18 | -13.05% |
| 2025-12-15 | -0.79 | -2.47 | -214.01% |
| 2025-09-08 | -0.95 | -0.89 | +6.10% |
| 2025-06-02 | -0.76 | -0.95 | -25.39% |